US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Turn Therapeutics (Direct Listing)

12.10

+0.46003.95%

Volume:176.32K

Turnover:2.17M

Market Cap:360.43M

PE:-41.43

High:13.05

Open:11.58

Low:11.31

Close:11.64

52wk High:26.50

52wk Low:2.57

Shares:29.79M

Float Shares:11.41M

Volume Ratio:1.65

T/O Rate:1.55%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.2921

EPS(LYR):-0.1152

ROE:-686.28%

ROA:-50.27%

PB:524.74

PE(LYR):-105.00

Loading ...

Overview Company News Filings

Turn Therapeutics Shares Rise on Expanded Phase 2 Study for Eczema Treatment

Turn Therapeutics - Gx-3 Shows Clinically Meaningful Efficacy in Patients with Easi Scores 1.1 to 7

THOMSON REUTERS

Turn Therapeutics Announces Final Stage 2 Design and Data-driven Expansion of Gx-03 Phase 2 Program in Atopic Dermatitis

THOMSON REUTERS

Turn Therapeutics - no Treatment-related Serious Adverse Events or Tolerability Issues Reported

THOMSON REUTERS

Turn Therapeutics Gains Ahead of Release of Dermatitis Drug Data

Turn Therapeutics to Host Webcast on GX-03 Atopic Dermatitis Phase 2 Interim Analysis

Turn Therapeutics Inc Expected to Post a Loss of 3 Cents a Share - Earnings Preview

Turn Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

Turn Therapeutics Highlights GX-03 Phase 2 Atopic Dermatitis Data

Turn Therapeutics Shares Higher on Favorable Interim Eczema Drug Results

Turn announces interim analysis findings from Phase 2 trial of GX-03

Turn Therapeutics Reports Positive Interim Phase 2 GX-03 Data

Turn Therapeutics says Phase 2 interim data show GX-03 hits 70.4% EASI-75 at week 4 in atopic dermatitis trial

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy From Phase 2 Gx-03 Trial in Moderate-to-Severe Atopic Dermatitis

THOMSON REUTERS

Turn Therapeutics - Interim Analysis Leads to Trial Enrollment and Endpoint Refinement

THOMSON REUTERS

Turn Therapeutics - No Treatment-Related Serious Adverse Events or Discontinuations Reported in Interim Analysis

THOMSON REUTERS

Turn Therapeutics announces peer-reviewed article on GX-03

Turn Therapeutics reports GX-03 cuts disease severity in IL-36 murine dermatitis study published in Journal of Dermatological Treatment

Turn Therapeutics CEO to Present at Jefferies Conference

Turn Therapeutics CEO presents at Jefferies Global Healthcare Conference

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/TTRX/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TTRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTRX\",,,,,undefined,":{"symbol":"TTRX","market":"US","secType":"STK","nameCN":"Turn Therapeutics (Direct Listing)","latestPrice":12.1,"timestamp":1791403200000,"preClose":11.64,"halted":0,"volume":176320,"delay":0,"changeRate":0.039518900343642534,"floatShares":11408100,"shares":29788000,"eps":-0.292051,"marketStatus":"Pre-Mkt","change":0.46,"latestTime":"10-08 04:39:14 EDT","open":11.58,"high":13.05,"low":11.31,"amount":2174834.37984,"amplitude":0.149485,"askPrice":13.1,"askSize":125,"bidPrice":4.87,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.292051,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791466200000},"marketStatusCode":1,"adr":0,"listingDate":1759896000000,"exchange":"NASDAQ","adjPreClose":12.1,"postHourTrading":{"tag":"盘后","latestPrice":12.2,"preClose":12.1,"latestTime":"19:30 EDT","volume":617,"amount":7497,"timestamp":1791415802454,"change":0.1,"changeRate":0.008264,"amplitude":0.008264},"volumeRatio":1.653121915106576,"impliedVol":1.5113,"impliedVolPercentile":0.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TTRX\",,,,,undefined,":{"symbol":"TTRX","floatShares":11408100,"roa":"-50.27%","roe":"-686.28%","lyrEps":-0.115242,"volumeRatio":1.653121915106576,"shares":29788000,"dividePrice":0,"high":13.05,"amplitude":0.149485,"preClose":11.64,"low":11.31,"week52Low":2.5701,"pbRate":"524.74","week52High":26.5,"institutionHeld":0,"latestPrice":12.1,"committee":-0.111111,"eps":-0.292051,"divideRate":0,"volume":176320,"delay":0,"ttmEps":-0.292051,"open":11.58,"prevYearClose":3.94,"prevWeekClose":13.33,"prevMonthClose":14.39,"prevQuarterClose":14.39,"fiveDayClose":14.39,"twentyDayClose":13.75,"sixtyDayClose":9.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TTRX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"TTRX","fiscalQuarterEnding":"2026/06","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.07},{"market":"US","date":"2026-05-11","symbol":"TTRX","fiscalQuarterEnding":"2026/03","expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778472000000,"reportTimeType":"post","actualEps":-0.03}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TTRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TTRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.3333,"hold":0,"sell":0.3333,"strongSell":0,"meanLabel":"BUY","meanPercent":0.3333,"analysts":3,"updateTime":1790308800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TTRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TTRX","date":"2026-10-06","current":-41.43112,"percent":0.37247,"low":-100.764104,"twenty":-53.053322,"median":-35.442633,"eighty":-27.33329,"high":-21.019642,"avg":-41.030539,"sd":15.437827,"marketCap":368180174},"quantilePoints":[{"date":"2025-10-10","current":-100.764104,"twenty":-95.944951,"median":-88.716222,"eighty":-81.487493,"marketCap":257809999},{"date":"2025-10-17","current":-61.772777,"twenty":-80.611283,"median":-71.301556,"eighty":-62.49565,"marketCap":158048738},{"date":"2025-10-24","current":-54.215469,"twenty":-75.594983,"median":-58.815569,"eighty":-54.127848,"marketCap":138712988},{"date":"2025-10-31","current":-57.391729,"twenty":-70.118673,"median":-57.391729,"eighty":-54.25928,"marketCap":146839608},{"date":"2025-11-07","current":-46.548635,"twenty":-64.664269,"median":-55.529784,"eighty":-49.111548,"marketCap":119097010},{"date":"2025-11-14","current":-44.796216,"twenty":-60.918473,"median":-54.215469,"eighty":-46.701972,"marketCap":114613358},{"date":"2025-11-21","current":-21.019642,"twenty":-57.501255,"median":-52.517813,"eighty":-44.182869,"marketCap":79796445},{"date":"2025-11-28","current":-27.302265,"twenty":-57.501255,"median":-48.301054,"eighty":-27.302265,"marketCap":103647044},{"date":"2025-12-05","current":-32.964383,"twenty":-57.391729,"median":-47.315318,"eighty":-27.302265,"marketCap":125142027},{"date":"2025-12-12","current":-24.897804,"twenty":-55.858362,"median":-45.508136,"eighty":-26.138816,"marketCap":94519037},{"date":"2025-12-19","current":-23.268976,"twenty":-55.63931,"median":-44.029532,"eighty":-25.595874,"marketCap":88335549},{"date":"2025-12-26","current":-23.036286,"twenty":-55.464068,"median":-42.496165,"eighty":-24.137684,"marketCap":87452193},{"date":"2026-01-02","current":-30.559922,"twenty":-54.828816,"median":-32.964383,"eighty":-24.075634,"marketCap":116014021},{"date":"2026-01-09","current":-36.066913,"twenty":-54.30309,"median":-35.136154,"eighty":-24.292811,"marketCap":136920100},{"date":"2026-01-16","current":-37.385488,"twenty":-54.149753,"median":-35.834223,"eighty":-24.680627,"marketCap":141925782},{"date":"2026-01-23","current":-36.687419,"twenty":-53.711649,"median":-35.834223,"eighty":-25.083956,"marketCap":139275715},{"date":"2026-01-30","current":-33.740015,"twenty":-52.638292,"median":-35.911787,"eighty":-25.45626,"marketCap":128086546},{"date":"2026-02-06","current":-28.698404,"twenty":-50.513483,"median":-35.446407,"eighty":-25.69184,"marketCap":108947177},{"date":"2026-02-13","current":-27.806427,"twenty":-48.322959,"median":-35.097373,"eighty":-25.925975,"marketCap":105560981},{"date":"2026-02-20","current":-26.371506,"twenty":-48.027239,"median":-33.584888,"eighty":-25.643857,"marketCap":100113622},{"date":"2026-02-27","current":-29.784289,"twenty":-47.359128,"median":-32.809256,"eighty":-25.86537,"marketCap":113069502},{"date":"2026-03-06","current":-26.21638,"twenty":-47.161981,"median":-31.723371,"eighty":-25.999203,"marketCap":99524718},{"date":"2026-03-13","current":-28.892312,"twenty":-46.395298,"median":-30.559922,"eighty":-26.076766,"marketCap":109683306},{"date":"2026-03-20","current":-26.604196,"twenty":-45.672425,"median":-29.706726,"eighty":-26.154329,"marketCap":100996977},{"date":"2026-03-27","current":-26.371506,"twenty":-45.1467,"median":-28.892312,"eighty":-26.154329,"marketCap":100113622},{"date":"2026-04-02","current":-24.160954,"twenty":-44.796216,"median":-28.775967,"eighty":-25.98369,"marketCap":91721745},{"date":"2026-04-10","current":-32.734315,"twenty":-44.029532,"median":-28.989266,"eighty":-26.061253,"marketCap":104556020},{"date":"2026-04-17","current":-31.894973,"twenty":-43.81048,"median":-29.784289,"eighty":-26.138816,"marketCap":101875096},{"date":"2026-04-24","current":-31.242152,"twenty":-42.496165,"median":-30.559922,"eighty":-26.21638,"marketCap":99789934},{"date":"2026-05-01","current":-34.415795,"twenty":-38.471374,"median":-30.882559,"eighty":-26.371506,"marketCap":109926804},{"date":"2026-05-08","current":-35.392229,"twenty":-38.238684,"median":-31.242152,"eighty":-26.371506,"marketCap":113045611},{"date":"2026-05-15","current":-31.212763,"twenty":-37.850868,"median":-31.242152,"eighty":-26.44907,"marketCap":119747920},{"date":"2026-05-22","current":-38.588913,"twenty":-38.045407,"median":-31.288782,"eighty":-26.44907,"marketCap":148046558},{"date":"2026-05-29","current":-41.228799,"twenty":-38.837373,"median":-31.468187,"eighty":-26.480095,"marketCap":158174492},{"date":"2026-06-05","current":-44.606299,"twenty":-41.306443,"median":-31.521933,"eighty":-26.518877,"marketCap":171132289},{"date":"2026-06-12","current":-45.499201,"twenty":-41.792847,"median":-31.925517,"eighty":-26.588683,"marketCap":174557914},{"date":"2026-06-18","current":-46.819144,"twenty":-43.898101,"median":-32.128124,"eighty":-26.604196,"marketCap":179621881},{"date":"2026-06-26","current":-52.952995,"twenty":-44.973973,"median":-32.641055,"eighty":-26.650734,"marketCap":203154432},{"date":"2026-07-02","current":-53.185927,"twenty":-45.699909,"median":-32.809256,"eighty":-26.681759,"marketCap":204048074},{"date":"2026-07-10","current":-68.40409,"twenty":-46.788086,"median":-33.107355,"eighty":-26.74381,"marketCap":262432632},{"date":"2026-07-17","current":-70.112251,"twenty":-47.348176,"median":-33.573656,"eighty":-26.867911,"marketCap":268986001},{"date":"2026-07-24","current":-73.606217,"twenty":-48.853305,"median":-34.461027,"eighty":-26.945474,"marketCap":282390619},{"date":"2026-07-31","current":-64.056043,"twenty":-51.501785,"median":-34.552888,"eighty":-26.992012,"marketCap":245751330},{"date":"2026-08-07","current":-74.615585,"twenty":-53.558617,"median":-35.327878,"eighty":-27.007525,"marketCap":286263064},{"date":"2026-08-14","current":-34.775161,"twenty":-54.193564,"median":-35.356755,"eighty":-27.085088,"marketCap":293710074},{"date":"2026-08-21","current":-33.646556,"twenty":-54.04617,"median":-35.233657,"eighty":-27.147139,"marketCap":284177901},{"date":"2026-08-28","current":-35.656885,"twenty":-53.776019,"median":-34.888704,"eighty":-27.147139,"marketCap":301157084},{"date":"2026-09-04","current":-35.515809,"twenty":-53.558617,"median":-34.775161,"eighty":-27.147139,"marketCap":299965562},{"date":"2026-09-11","current":-47.189823,"twenty":-53.185927,"median":-34.825901,"eighty":-27.147139,"marketCap":398563975},{"date":"2026-09-18","current":-48.741656,"twenty":-53.120207,"median":-35.280767,"eighty":-27.224702,"marketCap":411670712},{"date":"2026-09-25","current":-46.766596,"twenty":-53.185927,"median":-35.368844,"eighty":-27.302265,"marketCap":394989410},{"date":"2026-10-02","current":-46.942941,"twenty":-53.120207,"median":-35.415544,"eighty":-27.302265,"marketCap":396478812},{"date":"2026-10-06","current":-43.592393,"twenty":-53.053322,"median":-35.442633,"eighty":-27.33329,"marketCap":368180174}],"updateTime":1791439212408},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TTRX\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2653719217","title":"Turn Therapeutics Shares Rise on Expanded Phase 2 Study for Eczema Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2653719217","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653719217?lang=en_us&edition=fundamental","pubTime":"2026-07-21 01:07","pubTimestamp":1784567220,"startTime":"0","endTime":"0","summary":"Turn Therapeutics shares rose after the company said it will add more patients to its Phase 2 study of GX-03, its treatment for atopic dermatitis.Shares were recently up 9.7% at $10.01 in late Monday morning trading after the company said it would expand the study in its second phase. The stock is up about 194% over the past three months.\"The purpose of a staged, adaptive clinical trial is to learn from the first stage to strengthen the second,\" Chief Executive Bradley Burnam said. \"GX-03 demonstrated meaningful activity across a wider spectrum of atopic dermatitis severity than we originally anticipated.\"The company said its expanded study will generate data that could support broader development and future labeling opportunities for GX-03.The program will expand to up to 135 patients from 50 and evaluate patients across the full range of disease severity, as measured by the Eczema Area and Severity Index.The company said enrollment continued during the review, no treatment related se","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4139","TTRX","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987886","title":"Turn Therapeutics - Gx-3 Shows Clinically Meaningful Efficacy in Patients with Easi Scores 1.1 to 7","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987886","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649987886?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:05","pubTimestamp":1783425923,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390I2:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987855","title":"Turn Therapeutics Announces Final Stage 2 Design and Data-driven Expansion of Gx-03 Phase 2 Program in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987855","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649987855?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:05","pubTimestamp":1783425923,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390I2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649982001","title":"Turn Therapeutics - no Treatment-related Serious Adverse Events or Tolerability Issues Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2649982001","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649982001?lang=en_us&edition=fundamental","pubTime":"2026-07-07 20:05","pubTimestamp":1783425923,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260707:nFWN4390I2:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649674308","title":"Turn Therapeutics Gains Ahead of Release of Dermatitis Drug Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2649674308","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649674308?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:28","pubTimestamp":1783373280,"startTime":"0","endTime":"0","summary":"Shares of Turn Therapeutics climbed ahead of the company's release of initial findings from a phase 2 trial of GX-03, its treatment for atopic dermatitis.Shares were up 2.9%, to $7.91, in after-hours trading Monday. The stock closed up 8%, at $7.69, having nearly doubled in value this year.The company said Monday that it would present findings from an initial analysis of data from the study on a Tuesday webcast. It would also share an optimized study design for the remaining stage of the phase 2 trial.Write to Elias Schisgall at elias.schisgall@wsj.com Dow Jones NewswiresJuly 06, 2026 17:28 ET Copyright  2026 Dow Jones & Company, Inc.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649679923","title":"Turn Therapeutics to Host Webcast on GX-03 Atopic Dermatitis Phase 2 Interim Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2649679923","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649679923?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:01","pubTimestamp":1783368073,"startTime":"0","endTime":"0","summary":"Turn Therapeutics to host webcast on GX-03 atopic dermatitis Phase 2 interim analysisTurn Therapeutics scheduled a live webcast for July 7, 2026, at 4:30 p.m. ET to present interim Phase 2 GX-03 atopi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL6m2zbb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648663245","title":"Turn Therapeutics Inc Expected to Post a Loss of 3 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2648663245","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648663245?lang=en_us&edition=fundamental","pubTime":"2026-07-03 19:02","pubTimestamp":1783076529,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Incexpected to post a loss of3cents a share - Earnings PreviewTurn Therapeutics IncTTRX.OQTTRX.Ois expected to  report resultson July 6  for the period ending June 30 2026LSEG's mean analyst estimate for Turn Therapeutics Inc is for a loss of 3 cents per share.The one available analyst rating on the shares is \"buy\".The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Turn Therapeutics Inc is $6.15, about 13.6% below its last closing price of $7.12This summary was machine generated July 3 at 11:02 GMT.  All figures in US dollars unless otherwise stated.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260703:nL8N4350N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645283844","title":"Turn Therapeutics Inc  expected to post a loss of 3 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2645283844","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645283844?lang=en_us&edition=fundamental","pubTime":"2026-06-23 19:01","pubTimestamp":1782212501,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc  expected to post a loss of3cents a share - Earnings Preview Turn Therapeutics Inc TTRX.OQ TTRX.O is expected to  report resultson June 25 (estimated) for the period ending June ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nL8N42V0QR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640905464","title":"Turn Therapeutics Highlights GX-03 Phase 2 Atopic Dermatitis Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2640905464","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640905464?lang=en_us&edition=fundamental","pubTime":"2026-06-03 18:35","pubTimestamp":1780482903,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc ( ($TTRX) ) has shared an update. On June 1, 2026, Turn Therapeutics released an updated investor presentation ahead of the 2...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-highlights-gx-03-phase-2-atopic-dermatitis-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-highlights-gx-03-phase-2-atopic-dermatitis-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TTRX","LENZ","BK4007","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640969988","title":"Turn Therapeutics Shares Higher on Favorable Interim Eczema Drug Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2640969988","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640969988?lang=en_us&edition=fundamental","pubTime":"2026-06-02 02:30","pubTimestamp":1780338600,"startTime":"0","endTime":"0","summary":"Turn Therapeutics shares were higher after the company reported favorable interim results from an eczema study with its lead drug candidate, GX-03.The stock rose 28% to $6.65 Monday and is up about 69% this year.Turn Therapeutics reported findings from the first 50 completed subjects enrolled in the Phase 2 clinical trial.Within the completed interim cohort, 92.6% of GX-03-treated subjects achieved at least a 50% reduction in overall eczema severity within four weeks compared to 65.2% for vehicle-treated subjects, the company said. GX-03 continued to demonstrate a favorable safety and tolerability profile.\"What became increasingly apparent during the interim review was the speed with which responses emerged,\" the company said. It said \"The consistency of response across earlier efficacy measures suggests clinically meaningful improvement may emerge sooner than originally anticipated, which could have important implications for both future regulatory strategy and patient outcomes.\". The","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","TTRX","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640968956","title":"Turn announces interim analysis findings from Phase 2 trial of GX-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2640968956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640968956?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:54","pubTimestamp":1780325675,"startTime":"0","endTime":"0","summary":"Turn Therapeutics (TTRX) announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind,...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/turn-announces-interim-analysis-findings-from-phase-2-trial-of-gx-03-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/turn-announces-interim-analysis-findings-from-phase-2-trial-of-gx-03-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640957153","title":"Turn Therapeutics Reports Positive Interim Phase 2 GX-03 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2640957153","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640957153?lang=en_us&edition=fundamental","pubTime":"2026-06-01 21:46","pubTimestamp":1780321572,"startTime":"0","endTime":"0","summary":"Turn Therapeutics Inc ( ($TTRX) ) has shared an announcement. On June 1, 2026, Turn Therapeutics reported interim results from the first 50 complet...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-reports-positive-interim-phase-2-gx-03-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-reports-positive-interim-phase-2-gx-03-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","BK4139","LENZ","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640432951","title":"Turn Therapeutics says Phase 2 interim data show GX-03 hits 70.4% EASI-75 at week 4 in atopic dermatitis trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2640432951","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640432951?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:30","pubTimestamp":1780317050,"startTime":"0","endTime":"0","summary":"Turn Therapeutics released interim Phase 2 results for topical GX-03 in adults with moderate-to-severe atopic dermatitis.The analysis showed faster, more substantial symptom improvement versus vehicle, with benefits deepening over the treatment period.Safety looked favorable, with no treatment-related serious adverse events or treatment-related discontinuations reported in the interim cohort.The readout prompted changes to enrollment criteria and endpoint priorities to sharpen the second stage of the ongoing trial.More detailed findings will be presented at the Jefferies Global Healthcare conference on June 4, 2026.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nNDL6rbjMs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951973","title":"Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy From Phase 2 Gx-03 Trial in Moderate-to-Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951973","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951973?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:30","pubTimestamp":1780317001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA6FMCWT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951204","title":"Turn Therapeutics - Interim Analysis Leads to Trial Enrollment and Endpoint Refinement","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951204","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951204?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:30","pubTimestamp":1780317001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA6FMCWT:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640512079","title":"Turn Therapeutics - No Treatment-Related Serious Adverse Events or Discontinuations Reported in Interim Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2640512079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640512079?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:30","pubTimestamp":1780317001,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260601:nTUA6FMCWT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638689194","title":"Turn Therapeutics announces peer-reviewed article on GX-03","url":"https://stock-news.laohu8.com/highlight/detail?id=2638689194","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638689194?lang=en_us&edition=fundamental","pubTime":"2026-05-27 22:27","pubTimestamp":1779892077,"startTime":"0","endTime":"0","summary":"Turn Therapeutics (TTRX) announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the ef...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/turn-therapeutics-announces-peer-reviewed-article-on-gx-03-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/turn-therapeutics-announces-peer-reviewed-article-on-gx-03-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4007","TTRX","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507056","title":"Turn Therapeutics reports GX-03 cuts disease severity in IL-36 murine dermatitis study published in Journal of Dermatological Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507056","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638507056?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:07","pubTimestamp":1779883646,"startTime":"0","endTime":"0","summary":"Turn Therapeutics reports GX-03 cuts disease severity in IL-36 murine dermatitis study published in Journal of Dermatological Treatment. Turn Therapeutics flagged peer-reviewed results already published on GX-03 in an IL-36-associated murine dermatitis model.The study showed GX-03 reduced visible disease severity versus no treatment, supporting activity in an inflammation setting linked to skin barrier disruption.No treatment-related safety issues were observed in the animal study.The publication underpins GX-03’s Phase 2 program in moderate-to-severe atopic dermatitis, supporting a localized, non-systemic development strategy.A follow-on mechanistic manuscript is under review, with additional publications planned.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL5YfDD5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636011859","title":"Turn Therapeutics CEO to Present at Jefferies Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2636011859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636011859?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:46","pubTimestamp":1779194770,"startTime":"0","endTime":"0","summary":"The latest update is out from Turn Therapeutics Inc ( ($TTRX) ). On May 19, 2026, Turn Therapeutics Inc. announced that Chief Executive Officer Bra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-ceo-to-present-at-jefferies-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/turn-therapeutics-ceo-to-present-at-jefferies-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4539","BK4139","TTRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636885577","title":"Turn Therapeutics CEO presents at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2636885577","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636885577?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:07","pubTimestamp":1779192470,"startTime":"0","endTime":"0","summary":"Turn Therapeutics will present at the Jefferies Global Healthcare Conference in New York City on June 4, 2026.Chief Executive Officer Bradley Burnam is scheduled to speak from 9:55 a.m. to 10:25 a.m. EDT.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL4B1Q1d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TTRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":47,"code":"91000000","status":"200"}]}}